cyclophosphamid
Showing 1 - 18 of 18
Glomerulonephritis Rapidly Progressive Trial (ALE.F02, Rituximab, GlucoCorticoid)
Not yet recruiting
- Glomerulonephritis Rapidly Progressive
- ALE.F02
- +5 more
- (no location specified)
Sep 14, 2023
AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- CD33/CLL1 dual CAR-NK cell
- +5 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 4, 2023
AML, Adult Trial in Hangzhou (QN-030a, Cyclophosphamid, Fludarabine)
Recruiting
- AML, Adult
- QN-030a
- +4 more
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Dec 29, 2022
AML, Adult Trial in Tianjin (QN-023a, Cyclophosphamid, Fludarabine)
Recruiting
- AML, Adult
- QN-023a
- +3 more
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Nov 3, 2022
Minimal Residual Disease Trial in Tianjin (QN-030a, Cyclophosphamid, Fludarabine)
Recruiting
- Minimal Residual Disease
- QN-030a
- +3 more
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Nov 3, 2022
AML, Adult Trial in Hangzhou (QN-023a, Cyclophosphamid, Fludarabine)
Recruiting
- AML, Adult
- QN-023a
- +4 more
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Dec 29, 2022
Early Luminal Breast Cancer and Pancreatic Cancer Patients
Recruiting
- Breast Cancer
- Pancreas Cancer
- mFOLFIRINOX
- +4 more
-
Moscow, Not Required, Russian FederationMoscow Clinical Scientific Center named after AS Loginov
Oct 12, 2022
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor Trial in Chapel Hill (ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine)
Recruiting
- Germ Cell Tumor
- Nonseminomatous Germ Cell Tumor
- ATLCAR.CD30 Cells
- +2 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Dec 13, 2022
Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Mitoxantrone hydrochloride liposome injection
- +4 more
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Aug 15, 2023
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
B-cell Lymphoma, B-cell Acute Lymphoblastic Leukemia Trial in Hangzhou (QN-019a, Rituximab, Cyclophosphamid)
Recruiting
- B-cell Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- QN-019a
- +4 more
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical College of Zhejiang Uni
May 17, 2022
Myeloid Leukemia, Acute, Chronic Myeloid Leukemia, MDS Trial in Saint Petersburg (Bendamustine Hydrochloride, Cyclophosphamid)
Recruiting
- Myeloid Leukemia, Acute
- +3 more
- Bendamustine Hydrochloride
- Cyclophosphamid
-
Saint Petersburg, Russian FederationRM Gorbacheva Research Institute
Apr 4, 2022
Relapsed or Refractory Multiple Myeloma Trial in Hangzhou (anti-BCMA CAR-T, Cyclophosphamid, Fludarabine)
Recruiting
- Relapsed or Refractory Multiple Myeloma
- anti-BCMA CAR-T
- +2 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Apr 4, 2021
Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer Trial in Herlev (Ipilimumab, Cyclophosphamid,
Recruiting
- Metastatic Ovarian Cancer
- +2 more
- Ipilimumab
- +5 more
-
Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK)
May 7, 2021
HER2-negative Breast Cancer, Neoadjuvant Chemo Trial in Hangzhou (Epirubicin, Cyclophosphamid, Docetaxel)
Recruiting
- HER2-negative Breast Cancer
- Neoadjuvant Chemotherapy
- Epirubicin
- +3 more
-
Hangzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 9, 2021
Acute Myeloid Leukemia in Remission, MDS, Chronic Myeloid Leukemia in Remission Trial in Belgium (Thymoglobulin, Melphalan,
Recruiting
- Acute Myeloid Leukemia in Remission
- +9 more
- Thymoglobulin
- +3 more
-
Antwerp, Belgium
- +9 more
Oct 5, 2021
Breast Cancer Trial in Munich (Docetaxel, Trastuzumab, Bevacizumab)
Terminated
- Breast Cancer
- Docetaxel
- +4 more
-
Munich, Bavaria, GermanyBreast Centre, University of Munich, LMU
Aug 9, 2018